Wedbush Maintains Outperform on Immunome, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has maintained an Outperform rating on Immunome (NASDAQ:IMNM) and increased the price target from $12 to $19.
January 23, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten maintains an Outperform rating on Immunome and raises the price target from $12 to $19, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst suggests a strong conviction in Immunome's future performance. This typically leads to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100